Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A.

Mol Cancer Ther. 2018 Mar;17(3):603-613. doi: 10.1158/1535-7163.MCT-17-0324. Epub 2017 Dec 13.

2.

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Bosotti R, Magnaghi P, Di Bella S, Cozzi L, Cusi C, Bozzi F, Beltrami N, Carapezza G, Ballinari D, Amboldi N, Lupi R, Somaschini A, Raddrizzani L, Salom B, Galvani A, Stacchiotti S, Tamborini E, Isacchi A.

Sci Rep. 2017 Aug 23;7(1):9226. doi: 10.1038/s41598-017-10044-3.

3.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.

Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.

4.

Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.

Modugno M, Banfi P, Gasparri F, Borzilleri R, Carter P, Cornelius L, Gottardis M, Lee V, Mapelli C, Naglich JG, Tebben A, Vite G, Pastori W, Albanese C, Corti E, Ballinari D, Galvani A.

Exp Cell Res. 2015 Mar 15;332(2):267-77. doi: 10.1016/j.yexcr.2014.11.022. Epub 2014 Dec 5.

PMID:
25486070
5.

Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.

Brasca MG, Nesi M, Avanzi N, Ballinari D, Bandiera T, Bertrand J, Bindi S, Canevari G, Carenzi D, Casero D, Ceriani L, Ciomei M, Cirla A, Colombo M, Cribioli S, Cristiani C, Della Vedova F, Fachin G, Fasolini M, Felder ER, Galvani A, Isacchi A, Mirizzi D, Motto I, Panzeri A, Pesenti E, Vianello P, Gnocchi P, Donati D.

Bioorg Med Chem. 2014 Sep 1;22(17):4998-5012. doi: 10.1016/j.bmc.2014.06.025. Epub 2014 Jun 21.

PMID:
25009002
6.

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A.

Mol Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001. Epub 2014 Jun 12.

7.

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.

Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, Polucci P, Ballinari D, Perrera C, Leone A, Cervi G, Casale E, Xiao Y, Wong C, Anderson DJ, Galvani A, Donati D, O'Brien T, Jackson PK, Isacchi A.

Nat Chem Biol. 2013 Sep;9(9):548-56. doi: 10.1038/nchembio.1313. Epub 2013 Jul 28.

PMID:
23892893
8.

NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.

Fogliatto G, Gianellini L, Brasca MG, Casale E, Ballinari D, Ciomei M, Degrassi A, De Ponti A, Germani M, Guanci M, Paolucci M, Polucci P, Russo M, Sola F, Valsasina B, Visco C, Zuccotto F, Donati D, Felder E, Pesenti E, Galvani A, Mantegani S, Isacchi A.

Clin Cancer Res. 2013 Jul 1;19(13):3520-32. doi: 10.1158/1078-0432.CCR-12-3512. Epub 2013 May 14.

9.

Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication.

Somaschini A, Amboldi N, Nuzzo A, Scacheri E, Ukmar G, Ballinari D, Malyszko J, Raddrizzani L, Landonio A, Gasparri F, Galvani A, Isacchi A, Bosotti R.

Genet Test Mol Biomarkers. 2013 Mar;17(3):254-9. doi: 10.1089/gtmb.2012.0359. Epub 2013 Jan 28.

PMID:
23356232
10.

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J.

Mol Cancer Ther. 2012 Apr;11(4):1006-16. doi: 10.1158/1535-7163.MCT-11-0765. Epub 2012 Feb 7.

11.

5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.

Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):96-101. doi: 10.1016/j.bmcl.2011.11.065. Epub 2011 Nov 23.

PMID:
22154349
12.

Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.

Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.

J Med Chem. 2010 Oct 28;53(20):7296-315. doi: 10.1021/jm100504d.

PMID:
20873740
13.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M.

Mol Cancer Ther. 2010 Aug;9(8):2243-54. doi: 10.1158/1535-7163.MCT-10-0190. Epub 2010 Aug 3.

14.

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.

Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B.

J Med Chem. 2010 May 13;53(9):3532-51. doi: 10.1021/jm901713n.

PMID:
20397705
15.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M.

Bioorg Med Chem. 2010 Mar 1;18(5):1844-53. doi: 10.1016/j.bmc.2010.01.042. Epub 2010 Jan 25.

PMID:
20153204
16.

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG.

J Med Chem. 2010 Mar 11;53(5):2171-87. doi: 10.1021/jm901710h.

PMID:
20141146
17.

Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.

Giardinà D, Martarelli D, Sagratini G, Angeli P, Ballinari D, Gulini U, Melchiorre C, Poggesi E, Pompei P.

J Med Chem. 2009 Aug 13;52(15):4951-4. doi: 10.1021/jm8016046.

PMID:
19719240
18.

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D'Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M.

J Med Chem. 2009 Aug 27;52(16):5152-63. doi: 10.1021/jm9006559.

PMID:
19603809
19.

Design, synthesis, and biological evaluation of levoglucosenone-derived ras activation inhibitors.

Müller C, Gomez-Zurita Frau MA, Ballinari D, Colombo S, Bitto A, Martegani E, Airoldi C, van Neuren AS, Stein M, Weiser J, Battistini C, Peri F.

ChemMedChem. 2009 Apr;4(4):524-8. doi: 10.1002/cmdc.200800416.

PMID:
19226500
20.

A model-based approach to the in vitro evaluation of anticancer activity.

Del Bene F, Germani M, De Nicolao G, Magni P, Re CE, Ballinari D, Rocchetti M.

Cancer Chemother Pharmacol. 2009 Apr;63(5):827-36. doi: 10.1007/s00280-008-0798-3. Epub 2008 Jul 29.

PMID:
18663447
21.

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.

Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C.

Nat Chem Biol. 2008 Jun;4(6):357-65. doi: 10.1038/nchembio.90. Epub 2008 May 11.

PMID:
18469809
22.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68.

23.

6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors.

Brasca MG, Albanese C, Amici R, Ballinari D, Corti L, Croci V, Fancelli D, Fiorentini F, Nesi M, Orsini P, Orzi F, Pastori W, Perrone E, Pesenti E, Pevarello P, Riccardi-Sirtori F, Roletto F, Roussel P, Varasi M, Vulpetti A, Mercurio C.

ChemMedChem. 2007 Jun;2(6):841-52.

PMID:
17450625
24.

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.

Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J.

Clin Cancer Res. 2006 Jul 1;12(13):4080-9.

25.

Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.

Ciomei M, Croci V, Ciavolella A, Ballinari D, Pesenti E.

Clin Cancer Res. 2006 May 1;12(9):2856-61.

26.

Catecholic flavonoids acting as telomerase inhibitors.

Menichincheri M, Ballinari D, Bargiotti A, Bonomini L, Ceccarelli W, D'Alessio R, Fretta A, Moll J, Polucci P, Soncini C, Tibolla M, Trosset JY, Vanotti E.

J Med Chem. 2004 Dec 16;47(26):6466-75.

PMID:
15588081
27.

In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time.

Germani M, Magni P, De Nicolao G, Poggesi I, Marsiglio A, Ballinari D, Rocchetti M.

Cancer Chemother Pharmacol. 2003 Dec;52(6):507-13. Epub 2003 Aug 16.

PMID:
12923660
28.

4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.

Palha JA, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti V, Merlini G, Saraiva MJ.

Am J Pathol. 2000 Jun;156(6):1919-25.

29.

Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.

Quintieri L, Rosato A, Amboldi N, Vizler C, Ballinari D, Zanovello P, Collavo D.

Br J Cancer. 1999 Mar;79(7-8):1067-73.

30.

Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P, Comoglio PM.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14379-83.

31.

Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases.

Mandruzzato S, Rosato A, Bronte V, Zanovello P, Amboldi N, Ballinari D, Collavo D.

Cancer Res. 1994 Feb 15;54(4):1016-20.

PMID:
8313356
32.

Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity.

Capolongo L, Amboldi N, Ballinari D, Cozzi P, Melegaro G, Ripamonti M, Vaghi F, Grandi M.

Acta Oncol. 1994;33(7):787-91.

PMID:
7993647
33.

Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.

Geroni C, Pesenti E, Tagliabue G, Ballinari D, Mongelli N, Broggini M, Erba E, D'Incalci M, Spreafico F, Grandi M.

Int J Cancer. 1993 Jan 21;53(2):308-14.

PMID:
8425770
34.

Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.

Pezzoni G, Grandi M, Biasoli G, Capolongo L, Ballinari D, Giuliani FC, Barbieri B, Pastori A, Pesenti E, Mongelli N, et al.

Br J Cancer. 1991 Dec;64(6):1047-50.

35.

[New anthracyclines and multidrug resistance].

Grandi M, Ballinari D, Capolongo L, Pastori A, Ripamonti M, Suarato A, Spreafico F.

Haematologica. 1991 Jun;76 Suppl 3:181-3. Review. Italian. No abstract available.

PMID:
1752512
36.

Selective DNA interaction of the novel distamycin derivative FCE 24517.

Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F, D'Incalci M.

Cancer Res. 1991 Jan 1;51(1):199-204.

37.

[Anthracycline++ resistance and possibilities of overcoming it].

Ballinari D, Suarato A, Grandi M, Spreafico F.

G Ital Chemioter. 1991 Jan-Dec;38(1-3):99-101. Italian. No abstract available.

PMID:
1365623
39.

Novel anthracycline analogs.

Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, Faiardi D, Spreafico F.

Cancer Treat Rev. 1990 Sep;17(2-3):133-8. Review. No abstract available.

PMID:
2272029
40.

Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.

Gianni L, Viganò L, Surbone A, Ballinari D, Casali P, Tarella C, Collins JM, Bonadonna G.

J Natl Cancer Inst. 1990 Mar 21;82(6):469-77.

PMID:
2313718
41.

Ultrastructural cytoskeleton alterations and modification of actin expression in the NIH/3T3 cell line after transformation with Ha-ras-activated oncogene.

Lombardi L, Ballinari D, Bongarzone I, Migliari M, Mondellini P, Traversari C, Modina S.

Cell Motil Cytoskeleton. 1990;15(4):220-9.

PMID:
1692516
42.

Characterization of papillomavirus polypeptides from bovine cutaneous fibropapillomas.

Della Torre G, Muttini M, Ballinari D, Ferrari G, Pierotti MA, Della Porta G.

J Gen Virol. 1988 Nov;69 ( Pt 11):2919-24.

PMID:
2846766
43.

Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: biochemical and functional studies.

Delia D, Traversari C, Ballinari D, Cattoretti G, Fontanella E, Polli N, Della Porta G.

Immunology. 1988 Aug;64(4):593-8.

44.

Monoclonal antibodies against NIH 3T3 cells transformed by human thyroid carcinoma DNA.

Alzani R, Pierotti MA, Ménard S, Canevari S, Fertonani ML, Ballinari D, Traversari C, Della Torre G, Radice P, Pilotti S, et al.

Hybridoma. 1988 Feb;7(1):7-18.

PMID:
3371999
45.

Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity.

Traversari C, Ferrari G, Grazioli L, Ballinari D, Colombo MP, Castelli C, Pierotti MA, Parmiani G.

Exp Clin Immunogenet. 1987;4(2):106-14.

PMID:
2978840
46.
47.

Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus.

Carbone G, Pierotti MA, Boiocchi M, De Leo AB, Ballinari D, Radice P, Borrello MG, Meseguer A, Cernuschi A, Parmiani G.

Cancer Res. 1985 Oct;45(10):4980-5.

48.

Disulfide-linked surface molecules of monoclonal antigen-specific suppressor T cells: evidence for T cell receptor structures.

Ballinari D, Castelli C, Traversari C, Pierotti MA, Parmiani G, Palmieri G, Ricciardi-Castagnoli P, Adorini L.

Eur J Immunol. 1985 Aug;15(8):855-60.

PMID:
3161748
49.

Ly-5 molecular forms in congenitally immunodeficient mice.

Pierotti MA, Traversari C, Ballinari D, Borrello MG, Parmiani G.

Exp Clin Immunogenet. 1984;1(2):75-82.

PMID:
6400994
50.

Role of the carbohydrate prosthetic groups in the biosynthesis of membrane antigens and in the H-2-restricted lysis of MBL-2 lymphoma cells.

Pierotti MA, Ballinari D, Colombo MP, Grazioli L, Parmiani G.

Transplant Proc. 1983 Dec;15(4):2068-73. No abstract available.

PMID:
6673209

Supplemental Content

Loading ...
Support Center